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unfortunate that he has not shared our favor-
able experience. He attributes this failure to
‘‘different environmental factors’’ between
Birmingham, Alabama, and Szczecin, Po-
land. Although the author may be correct
and there indeed may be environmental fac-
tors at play, I wonder if other reasons may
explain his findings, because we are aware
of several different groups in different parts
of the country who have used the criteria of
450 mL/d or less with good results.
The author removed the chest tubes on
postoperative day (POD) 1 in 15 patients.
This is not our experience or our recommen-
dation. As shown in Table 1, no patients had
a chest tube removed on POD 1. However,
I agree that our article is not clear on this
point. We rarely if ever remove a chest
tube on POD 1 after a lobectomy or bilobec-
tomy because we believe there is little
advantage to doing so. Although there is
obvious pain involved with any indwelling
tube, and we have written extensively on
the advantage of fast-tracking patients and
that early tube removal improves ambula-
tion and pulmonary toilet, we have not con-
doned the removal of tubes on POD 1 after
lobectomy. How many of Dr Grodzki’s pa-
tients who returned for drainage was in this
group of 15 patients? Second, and most im-
portant, is that Dr Grodzki does not tell us
how many of his patients who underwent
pleural fluid drainage were actually symp-
tomatic with shortness of breath from their
effusion and how many were better once
drainage was performed. It has been my
experience in the United States that it is
common to see residual fluid and postoper-
ative changes in the lung and pleural space
after lobectomy, especially after bilobec-
tomy. These are normal postoperative find-
ings and are all too often overtreated by
our medical colleagues. We often have to
convince physicians not to overtreat these
‘‘pleural space abnormalities of air or some
fluid’’ after thoracotomy and to leave the
asymptomatic patient alone. Too often the
chest roentgenogram is treated as opposed
to the patient. Patients often receive antibi-
otics for ‘‘pneumonia’’ and diuretics or thor-
acentesis for fluid that never required
treatment in the first place. Thus, it would
be important to know how many of his pa-
tients were symptomatic and even more
important to know how many were dramat-
ically better once the fluid was drained.
Finally, because most of his patients under-
went a single thoracentesis, are we to be-
lieve that 1 tap, which rarely removes all
of the fluid, completely resolved a pleural
space problem? In our experience it does
not.
We appreciate Dr Grodzki’s letter, and
we agree that the pleural space is a mystery.
We look forward to further prospective
studies in this regard.
Robert J. Cerfolio, MD
General Thoracic Surgery
University of Alabama at Birmingham
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help of a thoracoscope and thoracoscopic
instruments.
However, we want to highlight that this
technique has already been published. We2
described in 2006 this same surgical
approach (Figures 1), which helped us
to ensure the mass nature, its resectability,
and its single location, since in a few cases
multiple tumors can be found operatively
but undetected by preoperative echocardi-
ography. In 1997, Espada and colleagues3
also published the use of a thoracoscope
through a left atrial approach to visualize
and resect a left ventricular fibroelastoma.
We are thankful for this other report,
which highlights a safe but unusual proce-
dure to remove left ventricular tumors.
Alexandre Le Guyader, MD
Marc Laskar, MD
Thoracic and Cardiovascular Surgery Department
University of Limoges and Limoges
University Hospital
Limoges, France
Letters to the EditorRemoval of left ventricular
tumors by a transaortic
transvalvular approach with the
help of thoracoscopic
instruments
To the Editor:
We read with interest the case report from
Walkes and colleagues1 describing their
new technique to resect a left ventricular
fibroelastoma. Indeed, a left ventricular
tumor location can be a real challenge for
surgeons when a transmitral approach is
performed. We agree with the authors that a
safe and more reasonable surgical approach
can be used through the aortic valve with theReferences
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785-7.Figure 1. Excision of a mitral valve papilary fibroelastoma through an aortotomy with the
help of a thoracoscope and thoracoscopic instruments.
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diac neoplasm, accounting for less than 10%
of all primary benign heart tumors. It is most
frequent in the left side of the heart and gen-
erally develops in the heart valves; however,
other endocardial heart locations have also
been described. Right PF arising from the
late them for this well-designed study, but I
also wish to add some brief comments. The
aim was to determine the impact of less-in-
vasive techniques for treatment of high-
risk patients with aortic valve disease by
using a self-expandable aortic bioprosthesis
Letters to the Editor3. Espada R, Talwalker NG, Wilcox G,
Kleiman NS, Verani MS. Visualization of
ventricular fibroelastoma with a video-assisted
thoracoscope. Ann Thorac Surg. 1997;63:
221-3.
doi:10.1016/j.jtcvs.2007.11.064Right atrial papillary
fibroelastoma associated with
atrial septal defect, persistent
superior vena cava, and
coronary artery disease
To the Editor:
We read with interest the article by Lauten
and coworkers1 regarding the successful re-
section of a right atrial papillary fibroelas-
toma (PF). We have additional surgical
experience with this infrequent location of
the neoplasm.
A 60-year-old man with a history of arte-
rial hypertension and a transient ischemic
attack underwent a transthoracic echocardio-
gram, which demonstrated a mass inside the
right atrium (RA). Further cardiologic evalua-
tion including transesophageal echocardio-
gram and complete cardiac catheterization
and coronary arteriography disclosed a tumor
in the RA, fenestrated atrial septal defect
(ASD), persistent left superior vena cava
(LSVC), and severe coronary artery disease
with tight stenosis in the proximal left anterior
descending coronary artery (LAD) and mid-
dle right coronary artery (RCA).The patient
underwent surgery on June 6, 1998. A median
sternotomy was performed. Under standard
cardiopulmonary bypass, with cannulation
of the aorta, both venae cavae, and the
LSVC, the aorta was crossclamped. Intermit-
tent cold blood cardioplegia was administered
and the three venae cavae were snared. A right
atriotomy was performed, a 231.5-cm gelat-
inous tumor attached to the muscular endocar-
dium of the RA was completely removed, an
ostium secundum type of ASD was closed
with an autologous pericardial patch, and
a double coronary bypass graft to the LAD
and RCA was carried out. The patient had
an uncomplicated surgery and recovery and
was discharged home 10 days after the oper-
ation. Gross and histologic examination of
the mass was typical of PF. At present, 9 years
6 months after the operation, the patient re-
mains asymptomatic. A recent transthoracic
echocardiogram showed no intracavitary
masses, closure of the interatrial septum, and
normal left ventricular function.
PF is an endocardial tumor that repre-
sents the second or third most common car-
nontricuspid valve or interatrial septum is
extremely uncommon. We only found
a few surgically treated patients.1-7 To the
best of our knowledge, excision of a free-
wall PF in association with closure of an
ASD and coronary artery bypass grafting
has not been previously reported.
Cipriano Abad, MDa
Pilar De la Rosa, MDb
Department of Cardiovascular Surgerya
Department of Pathologyb
Hospital Universitario
de Gran Canaria Dr Negrin
Las Palmas de Gran Canaria, Spain
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The present and the future in
aortic stenosis management:
Are there factors that might
preclude surgery?
To the Editor:
I read with great interest the article by Ber-
trand Marcheix and associates.1 I congratu-
(CoreValve Inc, Paris, France) suitable for
percutaneous retrograde delivery. The
mean logistic EuroSCORE was 32%. Of
10 patients undergoing successful implants,
2 died within 30 days and a third died later,
for an overall 30% hospital mortality. Vas-
cular complications were observed in 5 pa-
tients. Mean intensive care unit stay was
4.6 days and hospital stay was 15 days.
The authors concluded that the technique
is a viable alternative in selected high-risk
patients.
With the aim of reducing surgical inva-
siveness, epidural anesthesia, maintaining
an autonomic ventilation, has been sug-
gested,2 and the outcomes of 30 consecutive
patients who underwent epidural awake aor-
tic valve surgery (47% female, mean age
78.1% 6 8, 20% multivessel coronary dis-
ease, mean Logistic-EuroScore 28.3) have
been presented at the European Association
for Cardio-thoracic Surgery meeting in
Geneva. One patient had a redo operation.
Associated surgical procedures included
coronary artery bypass grafting (17%), as-
cending aorta replacement (10%), mitral
valve surgery (10%), and pulmonary vein
isolation to treat atrial fibrillation. Unless
emergency, no other exclusion criteria
were considered. One patient died, for an
operative mortality of 3%, and 2 patients
died during the follow-up period (natural
death). All other complications occurred
rarely (stroke, no cases; bowel ischemia,
no cases; prolonged mechanical ventilation,
2 cases; myocardial infarction, 1 case). Me-
dian stays in the ward and the intensive care
unit were 4.5 days and 1 day, respectively.
Seven patients have been transferred to the
ward within 3 hours after surgery and 19
patients in 12 hours or less.
The goal of aortic valve stenosis treat-
ment is to achieve a complete regression of
symptoms while offering the lowest mor-
bidity and mortality. The main reason that
percutaneous interventions are more accept-
able to the patients is the simplicity. Unfor-
tunately, interventional cardiologists and
cardiac surgeons are going to rethink the
management of high-risk aortic stenosis1,3,4
without a well-founded clinical program
and forgetting the patients’ and economic
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